Circulating tumor cell analysis in metastatic triple-negative breast cancers

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1098-1105

  Magbanua, Mark Jesus M ^a   Carey, Lisa A ^b   DeLuca, Amy ^a   Hwang, Jimmy ^a   Scott, Janet H ^a   Rimawi, Mothaffar F ^c   Mayer, Erica L ^d   Marcom, P Kelly ^e   Liu, Minetta C ^f   Esteva, Francisco J ^g   Park, John W ^a   Rugo, Hope S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB;

ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER PROGNOSIS; CELL ASSAY; CELL COUNT; CELL VIABILITY; CIRCULATING TUMOR CELL; CIRCULATING TUMOR CELL ANALYSIS; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; IMMUNOMAGNETIC ENRICHMENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; CLINICAL TRIAL; DISEASE COURSE; FEMALE; METABOLISM; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR EMBOLISM;

CELL COUNT; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84927728470     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1948     Document Type: Article

References (34)

1. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
2. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153-9.
3. Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, MavroudisD, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15:406-14.
4. Consoli F, Grisanti S, Amoroso V, Almici C, Verardi R, Marini M, et al. Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial. Tumori 2011;97:737-42.
5. Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 2011;31:979-84.
6. Martin M, Custodio S, de Las Casas ML, Garcia-Saenz JA, de la Torre JC, Bellon-Cano JM, et al. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. Oncologist 2013;18:917-23.
7. Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010;17:199-204.
8. Nole F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19:891-7.
9. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012;23: 618-24.
10. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-9.
11. Magbanua MJ, Park JW. Advances in genomic characterization of circulating tumor cells. Cancer Metastasis Rev 2014;33:757-69.
12. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-40.
13. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, et al. Genomic profiling of isolated circulating tumor cells frommetastatic breast cancer patients. Cancer Res 2013;73:30-40.
14. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012;30: 2615-23.
15. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-8.
16. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, et al. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 2007;99:519-24.
17. Magbanua MJ, Park JW. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods 2013;64:114-8.
18. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, et al. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 2012;12:78.
19. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012;10:138.
20. Park JW. Disseminated tumor cells: the method is the message. Breast Cancer Res Treat 2011;125:739-40.
21. Muller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012;14:R118.
22. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
23. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
24. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012;23:1144-50.
25. Jiang ZF, Cristofanilli M, Shao ZM, Tong ZS, Song EW, Wang XJ, et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triplenegative (CBCSG004): a multicenter, double-blind, prospective trial. Ann Oncol 2013;24:2766-72.
26. WallwienerM, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013;137:503-10.
27. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61-6.
28. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013;73: 2965-75.
29. Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, et al.Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 2013;110:21083-8.
30. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011;17:3600-18.
31. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005;65:4993-7.
32. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 2014;511:319-25.
33. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
34. Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacon JI, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 2014;111:1532-41.